A detailed history of Marshall Wace, LLP transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 19,614 shares of TYRA stock, worth $274,596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,614
Holding current value
$274,596
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.7 - $24.36 $327,553 - $477,797
19,614 New
19,614 $461,000
Q1 2024

May 15, 2024

SELL
$11.61 - $20.0 $120,256 - $207,160
-10,358 Reduced 34.53%
19,643 $322,000
Q4 2023

Feb 14, 2024

BUY
$11.01 - $14.95 $330,311 - $448,514
30,001 New
30,001 $415,000

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $588M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.